IMD 1618
Alternative Names: IMD-1618Latest Information Update: 25 Dec 2023
At a glance
- Originator Shanghai Affinity Biopharmaceutical
- Class Antineoplastics; Immunotherapies
- Mechanism of Action CD3 antigen inhibitors; Claudin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Dec 2023 IMD 1618 is available for licensing as of 22 Dec 2023. http://www.affinitybiopharma.com/en/cooperation.html (Shanghai Affinity Biopharmaceutical website, December 2023)
- 22 Dec 2023 Preclinical trials in Solid tumours in China (Parenteral) (Shanghai Affinity Biopharmaceutical pipeline, December 2023)